Datasheet

生物学的記述

Specificity	Phospho-Smad2/Smad3 (Thr8) Antibody (Rabbit mAb) [A2E13] detects endogenous levels of total Smad2/Smad3 protein only when it is phosphorylated at Thr8.
Background	Phospho-Smad2/Smad3 (Thr8) refers to a linker-region phosphorylated form of the receptor-regulated Smads Smad2 and Smad3, which are core intracellular transducers of TGF-β superfamily signaling and function as sequence-specific transcriptional modulators once activated and assembled into complexes with Smad4. These proteins share the conserved MH1 DNA-binding domain, MH2 transcriptional effector domain and a central linker segment that integrates inputs from multiple kinases; the Thr8 site lies in the N‑terminal portion of the protein and contributes to the broader pattern of linker phosphorylation that shapes how Smad2/3 respond to TGF-β and cooperating pathways. Canonical TGF-β signaling induces C‑terminal SSXS motif phosphorylation of Smad2 and Smad3 by type I receptor kinases, creating the pSmad2C and pSmad3C forms that associate with Smad4, translocate to the nucleus and regulate target genes involved in growth inhibition, differentiation and extracellular matrix production. Additional phosphorylation events within the linker region, including at threonine and serine residues near the N‑terminus and central linker, are mediated by cyclin-dependent kinases, MAPKs and other kinases activated by Ras and stress pathways, generating composite species phosphorylated at both the C‑terminal and linker regions, such as pSmad2L/C and pSmad3L/C, that modify DNA-binding affinity, cofactor recruitment and nuclear retention. These doubly phosphorylated Smad2/3 forms transmit a qualitatively distinct TGF-β signal in later stages of tumor progression, where CDK4- and JNK-driven linker phosphorylation converts an originally growth‑inhibitory pathway into one that supports proliferation and invasion by upregulating c‑Myc and matrix metalloproteinase‑9 and by enhancing migratory and invasive gene expression programs in colorectal cancer. Linker phosphorylation state also influences how Smad2 and Smad3 act as cofactors for other transcription factors, including STAT3 in Th17 differentiation, where differential phosphorylation patterns determine whether Smad2 or Smad3 cooperate with STAT3 to promote or restrain IL‑17–associated gene expression, highlighting the importance of specific phospho‑isoforms in immune cell fate decisions. Smad2 and Smad3, despite similar domain organization, have distinct sensitivities and roles in TGF‑β signaling, and linker phospho‑sites such as Thr8 contribute to selective activation profiles and context‑dependent target gene regulation in epithelial cells, fibroblasts and immune cells. In cancer, accumulation of Smad2/3 species phosphorylated at both linker and C‑terminal regions at invasive fronts of TGF‑β–producing colorectal tumors correlates with malignant behavior, suggesting that detection of specific phospho‑Smad2/3 forms is informative for assessing pathway rewiring from tumor suppression to tumor promotion. Antibodies specific for phospho‑Smad2/Smad3 (Thr8) recognize Smad2/3 only when phosphorylated at this site and are used to monitor noncanonical or linker‑biased TGF‑β/BMP signaling inputs and to distinguish early C‑terminal activation from later mixed linker/C‑terminal signaling states in tissues or cell models. The Thr8‑phosphorylated Smad2/3 species sit within a broader network of reversible Smad phosphorylation that fine‑tunes the strength, duration and qualitative output of TGF‑β superfamily signals, linking ligand–receptor activation to specific transcriptional programs in development, immunity and cancer progression.

Specificity

Phospho-Smad2/Smad3 (Thr8) Antibody (Rabbit mAb) [A2E13] detects endogenous levels of total Smad2/Smad3 protein only when it is phosphorylated at Thr8.

Background

Phospho-Smad2/Smad3 (Thr8) refers to a linker-region phosphorylated form of the receptor-regulated Smads Smad2 and Smad3, which are core intracellular transducers of TGF-β superfamily signaling and function as sequence-specific transcriptional modulators once activated and assembled into complexes with Smad4. These proteins share the conserved MH1 DNA-binding domain, MH2 transcriptional effector domain and a central linker segment that integrates inputs from multiple kinases; the Thr8 site lies in the N‑terminal portion of the protein and contributes to the broader pattern of linker phosphorylation that shapes how Smad2/3 respond to TGF-β and cooperating pathways. Canonical TGF-β signaling induces C‑terminal SSXS motif phosphorylation of Smad2 and Smad3 by type I receptor kinases, creating the pSmad2C and pSmad3C forms that associate with Smad4, translocate to the nucleus and regulate target genes involved in growth inhibition, differentiation and extracellular matrix production. Additional phosphorylation events within the linker region, including at threonine and serine residues near the N‑terminus and central linker, are mediated by cyclin-dependent kinases, MAPKs and other kinases activated by Ras and stress pathways, generating composite species phosphorylated at both the C‑terminal and linker regions, such as pSmad2L/C and pSmad3L/C, that modify DNA-binding affinity, cofactor recruitment and nuclear retention. These doubly phosphorylated Smad2/3 forms transmit a qualitatively distinct TGF-β signal in later stages of tumor progression, where CDK4- and JNK-driven linker phosphorylation converts an originally growth‑inhibitory pathway into one that supports proliferation and invasion by upregulating c‑Myc and matrix metalloproteinase‑9 and by enhancing migratory and invasive gene expression programs in colorectal cancer. Linker phosphorylation state also influences how Smad2 and Smad3 act as cofactors for other transcription factors, including STAT3 in Th17 differentiation, where differential phosphorylation patterns determine whether Smad2 or Smad3 cooperate with STAT3 to promote or restrain IL‑17–associated gene expression, highlighting the importance of specific phospho‑isoforms in immune cell fate decisions. Smad2 and Smad3, despite similar domain organization, have distinct sensitivities and roles in TGF‑β signaling, and linker phospho‑sites such as Thr8 contribute to selective activation profiles and context‑dependent target gene regulation in epithelial cells, fibroblasts and immune cells. In cancer, accumulation of Smad2/3 species phosphorylated at both linker and C‑terminal regions at invasive fronts of TGF‑β–producing colorectal tumors correlates with malignant behavior, suggesting that detection of specific phospho‑Smad2/3 forms is informative for assessing pathway rewiring from tumor suppression to tumor promotion. Antibodies specific for phospho‑Smad2/Smad3 (Thr8) recognize Smad2/3 only when phosphorylated at this site and are used to monitor noncanonical or linker‑biased TGF‑β/BMP signaling inputs and to distinguish early C‑terminal activation from later mixed linker/C‑terminal signaling states in tissues or cell models. The Thr8‑phosphorylated Smad2/3 species sit within a broader network of reversible Smad phosphorylation that fine‑tunes the strength, duration and qualitative output of TGF‑β superfamily signals, linking ligand–receptor activation to specific transcriptional programs in development, immunity and cancer progression.

使用情報

Application

WB, IP, IF

Dilution

WB	IP	IF
1:1000	1:30	1:50

Reactivity

Mouse, Rat, Human

Source

Rabbit Monoclonal Antibody

MW

52 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

プロトコール

References

https://pubmed.ncbi.nlm.nih.gov/19114991/
https://pubmed.ncbi.nlm.nih.gov/19531654/

Phospho-Smad2/Smad3 (Thr8) Antibody (Rabbit mAb) [A2E13]

生物学的記述

使用情報

References

Application Data